2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176464
    GSK2220691 1206619-37-5 99.96%
    SK2220691 is a potent TRPV4 inhibitor. SK2220691 inhibits pulmonary edema induced by GSK1016790. SK2220691 inhibits HCl-induced increases in key factors such as VEGF, keratinocyte-derived chemokine (KC; CXCL1), and granulocyte colony-stimulating factor (GCSF).
    GSK2220691
  • HY-176510
    Elafibranor sulfoxide
    Elafibranor (GFT505) sulfoxide is a sulfoxide metabolite of Elafibranor (HY-16737). Elafibranor is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis.
    Elafibranor sulfoxide
  • HY-176710
    PAD-PF2 99.94%
    PAD-PF2 is a PAD family inhibitor, as well as a κ-opioid receptor agonist (EC50 = 7.55 μM) and an M1 muscarinic acetylcholine receptor antagonist (IC50 = 12.3 μM). The IC50 values of PAD-PF2 against PAD1, PAD2, PAD3 and PAD4 are 109 nM, 27.9 nM, 106 nM and 20.1 nM, respectively. PAD-PF2 binds to the common allosteric pocket of PAD1-4, and its inhibitory effects on PAD2 and PAD4 are Ca2+-dependent. PAD-PF2 inhibits protein citrullination in neutrophils. PAD-PF2 is applicable to research related to rheumatoid arthritis, neurodegenerative diseases and cancer.
    PAD-PF2
  • HY-176865
    Anti-inflammatory agent 106 2460280-43-5
    Anti-inflammatory agent 106 (Example 2) is a derivative of Paeonol (HY-N0159). Anti-inflammatory agent 106 has potent anti-inflammatory activity. Anti-inflammatory agent 106 effectively inhibits xylene-induced ear swelling in mouse models. Anti-inflammatory agent 106 can be used for inflammatory diseases like rheumatoid arthritis, psoriasis and type 1 diabetes research.
    Anti-inflammatory agent 106
  • HY-176919
    PROTAC STAT6 degrader-3 3077385-98-6 98.66%
    PROTAC STAT6 degrader-3 is a potent STAT6 PROTAC degrader with a DC50 of less than 1 nM. PROTAC STAT6 degrader-3 can be used for research on allergic/inflammatory diseases and cancer.
    PROTAC STAT6 degrader-3
  • HY-177338
    STING agonist-45 2361424-97-5 99.10%
    STING agonist-45 is a selective STING agonist (EC50 = 0.28 μM). STING agonist-45 activates the innate immune response through the cGAS-STING pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust STING activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8+ T cell infiltration in mouse models. STING agonist-45 is promising for the study of STING-related diseases.
    STING agonist-45
  • HY-177435
    FAPI-800CW 99.40%
    FAPI-800CW is a near-infrared (NIR) fluorescent-labeled fibroblast activation protein (FAP) inhibitor. FAPI-800CW shows specific uptake in inflamed paws in collagen-induced arthritis (CIA) model mice. FAPI-800CW can be used for in vivo molecular imaging of FAP expression in inflammatory diseases such as rheumatoid arthritis (RA) to monitor joint inflammation and disease activity.
    FAPI-800CW
  • HY-178234
    LY237 1892576-07-6 99.96%
    LY237 is a highly efficient complete agonist of GPR84 (pEC50 = 10.15). LY237 can be used for research on inflammation and fibrosis conditions.
    LY237
  • HY-178793
    MrgprX2 antagonist-9 3095296-92-4 99.92%
    MrgprX2 antagonist-9 is an MRGPRX2 antagonist with an IC50 of 0.1-100 nM. MrgprX2 antagonist-9 can be used for the research of inflammatory diseases.
    MrgprX2 antagonist-9
  • HY-18234C
    Leupeptin Ac-LL hydrochloride 24125-16-4
    Leupeptin Ac-LL (hydrochloride) is the hydrochloride form of Leupeptin Ac-LL (HY-18234B). Leupeptin Ac-LL (hydrochloride) has better inhibition than Leupeptin Ac-LL.
    Leupeptin Ac-LL hydrochloride
  • HY-182757
    Y1693 2812381-74-9 99.91%
    Y1693 is an orally active RANKL inhibitor with a Kd of 5.03 μM for hRANKL. Y1693 inhibits the activation of the downstream c-fos/NFATc1 signaling pathway by blocking its interaction with RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation and bone resorptive activity, while downregulating the mRNA and protein expressions of TRAP, cathepsin K, c-fos and NFATc1. Y1693 shows no obvious cytotoxicity to bone marrow-derived macrophages and osteoclast precursor cells, and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research related to osteoporosis and periodontal diseases.
    Y1693
  • HY-185011
    AM9053 157469-21-1 98.36%
    AM9053 is a selective, effective and slowly reversible inhibitor of N-acyl ethanolamine acid amidease (NAAA) (IC50 = 30 nM). The effect of AM9053 on FAAH activity is limited (IC50 > 100 nM). AM9053 inhibits the proliferation of colorectal cancer cells by activating the PPAR-α and TRPV1 dependent mechanisms and induces S-phase cell cycle arrest. AM9053 alleviates intestinal fibrosis by regulating macrophage activity and inhibiting the IL-23 signaling pathway. AM9053 leads to an increase in NAE levels, especially PEA and OEA. AM9053 can be used for the study of colorectal cancer and intestinal fibrosis.
    AM9053
  • HY-186038
    Cyanoethyl dimethyldithiocarbamate 10264-38-7
    Cyanoethyl dimethyldithiocarbamate, a dithiocarbamate-related substance, is a contact allergen. Cyanoethyl dimethyldithiocarbamate can be found in accelerator-free and conventional nitrile gloves. Cyanoethyl dimethyldithiocarbamate can be used for the research of allergic contact dermatitis.
    Cyanoethyl dimethyldithiocarbamate
  • HY-186067
    PROTAC BCL6 Degrader-3 3005272-58-9 99.76%
    PROTAC BCL6 Degrader-3 (compound 92) is a BCL6 PROTAC degrader. PROTAC BCL6 Degrader-3 can be used for the study of cancer or an autoimmune disease.
    PROTAC BCL6 Degrader-3
  • HY-A0143A
    Dihomo-γ-linolenic acid sodium 65881-87-0 99.9%
    Dihomo-γ-linolenic acid (DGLA; all-cis-8,11,14-Eicosatrienoic acid) sodium is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid (sodium) attenuates atherosclerosis in the apolipoprotein E deficient mouse model system.
    Dihomo-γ-linolenic acid sodium
  • HY-B0004S
    Doxofylline-d6 1219805-99-8 99.67%
    Doxofylline-d6 is the deuterium labeled Doxofylline. Doxofylline is an antagonist of adenosine A1 receptor which also inhibits phosphodiesterase IV.
    Doxofylline-d6
  • HY-B0010A
    Arformoterol 67346-49-0 ≥98.0%
    Arformoterol ((R,R)-Formoterol), the (R,R)-enantiomer of Formoterol, is a long-acting β2-adrenergic receptor (β2-AR) agonist, with a Kd of 2.9 nM. Arformoterol can be used for the research of chronic obstructive pulmonary disease (COPD).
    Arformoterol
  • HY-B0212R
    Sulfapyridine (Standard) 144-83-2 99.86%
    Sulfapyridine (Standard) is the analytical standard of Sulfapyridine. This product is intended for research and analytical applications. Sulfapyridine, a major metabolite of Sulfasalazine, is a sulfonamide antibiotic agent. Sulfapyridine inhibits recombinant P. carinii dihydropteroate synthetase (DHPS) with an IC50 of 0.18 μM. Sulfapyridine has antibacterial, anti-inflammatory and anti-rheumatic activities.
    Sulfapyridine (Standard)
  • HY-B0290A
    Pranlukast hemihydrate 150821-03-7 99.28%
    Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
    Pranlukast hemihydrate
  • HY-B0303R
    Diphenhydramine (Standard) 58-73-1 98.69%
    Diphenhydramine (Standard) is the analytical standard of Diphenhydramine. This product is intended for research and analytical applications. Diphenhydramine is a first-generation histamine H1-receptor antagonist with anti-cholinergic effect. Diphenhydramine hydrochloride can across the ovine blood-brain barrier (BBB) .
    Diphenhydramine (Standard)
Cat. No. Product Name / Synonyms Application Reactivity